Pancreatic Cancer
Treatment for a recurrence or for metastases
If your pancreatic cancer comes back, it can be in the pancreas or it can spread somewhere else, like the liver or the lungs. Your doctor may offer you more treatment to:
- Get rid of the tumours
- Slow the growth
- Treat symptoms
- Improve your quality of life
(also see ‘Pain management and other palliative care’).
Most people we spoke to had chemotherapy when their cancer came back. Some of them had it in a clinical trial. The chemotherapy drugs used to treat disease recurrence or spread were sometimes different than they’d had before.
When Peter's cancer had spread to the liver he had a different chemotherapy regimen. Low blood counts prevented two out of every three intended treatments.
When Peter's cancer had spread to the liver he had a different chemotherapy regimen. Low blood counts prevented two out of every three intended treatments.
Chemotherapy can damage your bone marrow and cause a drop in the number of blood cells. You are then more likely to get an infection, anaemia, bleeding or bruising. If your blood count is low, there may be a delay to your chemotherapy.
Hamish was first given gemcitabine but his blood counts fell so low that capecitabine capsules were used instead.
Hamish was first given gemcitabine but his blood counts fell so low that capecitabine capsules were used instead.
Some people carried on with chemotherapy. Others had stopped it after a few months because their tumours had shrunk or they were having bad side effects.
People whose tumours had shrunk had periods of ‘watchful waiting’. More treatment was given if necessary. Bob’s cancer was not suitable for surgery. He was given chemotherapy which helped to control his pain. He was expecting to stop this treatment soon.
Bob got his chemotherapy through a PICC line (peripherally inserted central catheter). A syringe driver infused the drugs slowly. He had nose bleeds.
Bob got his chemotherapy through a PICC line (peripherally inserted central catheter). A syringe driver infused the drugs slowly. He had nose bleeds.
After David’s cancer came back, he took part in a clinical trial that involved three different chemotherapy drugs. He vomited blood and had bleeding from his bottom. The bleeding could have been due to the drugs. As the treatment went on, he found it harder to put up with the side effects.
David had serious side effects from chemotherapy. The thought of the treatment made him feel sick while driving to the hospital.
David had serious side effects from chemotherapy. The thought of the treatment made him feel sick while driving to the hospital.
Some people had radiotherapy as well as chemotherapy after a recurrence. Audrey had both at the same time in the hope that it would keep the symptoms under control. It stopped her pain.
David had radiotherapy after finishing his chemotherapy. Adrian had one session of radiotherapy for the pain from a secondary tumour at the top of his leg. Others had Sterotactic Ablative Radiotherapy (SABR).
When Audrey's cancer came back she started intravenous gemcitabine again, this time with radiotherapy.
When Audrey's cancer came back she started intravenous gemcitabine again, this time with radiotherapy.
Adrian has metastases in many places. He had radiotherapy to treat a secondary in his hip bone. The radiotherapy made him very tired.
Adrian has metastases in many places. He had radiotherapy to treat a secondary in his hip bone. The radiotherapy made him very tired.
Vicky had a rare type of pancreatic cancer, a neuroendocrine tumour. When it spread to her liver she had radiofrequency ablation which uses heat to destroy cancer cells.
Helen also hoped to have radiofrequency ablation for a tumour in her liver. However, a CT scan showed that another tumour had appeared in her liver. The consultant couldn’t consider this treatment as an option until he was sure that no more tumours would appear. This upset Helen so she joined a chemotherapy clinical trial instead. When we spoke to her she had been having chemotherapy on that for 9 months.
Last reviewed November 2020
Last updated November 2020
Next review November 2023
Copyright © 2024 University of Oxford. All rights reserved.